Anglo-Swedish drugmaker AstraZeneca said on Tuesday it will acquire biotechnology firm TeneoTwo in a deal worth up to $1.27 billion (€1.22 billion), in a move to bolster its blood cancer portfolio.
The deal includes the US-based company’s experimental treatment for a type of non-Hodgkin lymphoma, AstraZeneca said in a statement.
The experimental therapy, a T-cell engager, is a part of the immunotherapy class of treatments that use the body's own defence mechanism to fight cancerous cells.
AstraZeneca said it has agreed to buy all outstanding equity of TeneoTwo for an upfront payment of $100 million on deal close, and additional milestone-related payments of up to $1.17 billion.
Wills without residuary clauses can see people inherit even if you didn’t want them to
An Irish businessman in Singapore: ‘You’ll get a year in jail if you are in a drunken brawl, so people don’t step out of line’
Balmoral shows ‘small’ investors the door
A helping hand with the cost of caring: what supports are available?
The transaction is likely to close in the third quarter of this year and not expected to impact AstraZeneca's 2022 outlook, the London-listed company said.
TeneoTwo was spun-off from Teneobio, which was bought by US biotechnology company Amgen last year. - Reuters
(c) Copyright Thomson Reuters 2022
